Connecticut is currently home to 1249 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
Recruiting
The goal of this observational study is to learn how the brain's information processing changes during and following administration of serotonergic psychedelics (psilocybin, N,N-Dimethyltryptamine/DMT, Lystergic Acid Diethylamide/LSD, etc.) for people with and without mental illness receiving serotonergic psychedelics through any clinical trial at Yale University. The main questions it aims to answer are: 1. Do serotonergic psychedelics cause the brain to rely on new information more than previ... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/12/2024
Locations: Connecticut Mental Health Center, Hamden, Connecticut
Conditions: OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer, Migraine, PTSD, PTSD - Post Traumatic Stress Disorder, Addiction, Tobacco Use Disorder, Obsessive Compulsive Disorder (OCD), Opioid Use Disorder
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
Recruiting
The COPE-AKI study is a randomized, pragmatic, parallel-arm trial comparing a multimodal intervention to usual care on hospital-free days through 90 days of study follow up. The primary study hypothesis is that patients randomized to the intervention will have increased odds of more hospital-free days through 90 days (primary clinical) compared to those randomized to usual care. Key secondary hypotheses will investigate the impact of the intervention on rates of major adverse kidney events, rate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Acute Kidney Injury
International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
Recruiting
The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Spontaneous Coronary Artery Dissection
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab
Recruiting
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation phase, a dose expansion phase, and phase 2A cohorts. Up to 200 patients will be accrued for this study. Up to 15 study sites in the United States will participate in the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Solid Tumor, Adult
Effects of Oral Tranexamic Acid Following Total Knee Arthroplasty
Recruiting
The primary purpose of this study is to evaluate postoperative pain. Secondary outcomes evaluated in this study will include range of motion (ROM), opioid consumption, and ambulation. Each outcome measure will be evaluated, oral tranexamic acid (TXA) in the experiment arm and placebo in the control arm, after total knee arthroplasty (TKA) at postoperative days 0-3, and weeks 1, 2, 6, and 12.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
12/09/2024
Locations: Trinity Health Of New England/CT Joint Replacement Institute, Hartford, Connecticut
Conditions: Postoperative Pain
Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)
Recruiting
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Intracerebral Hemorrhage
Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients
Recruiting
HIV-infected (HIV+) individuals who agree to accept and receive a solid organ transplant from an HIV+ deceased donor will be followed to determine the safety and efficacy of this practice. Some HIV+ individuals who receive a solid organ transplant from HIV-uninfected (HIV-) donors will also be followed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: HIV Infection
Brain Oxygen Optimization in Severe TBI, Phase 3
Recruiting
BOOST3 is a randomized clinical trial to determine the comparative effectiveness of two strategies for monitoring and treating patients with traumatic brain injury (TBI) in the intensive care unit (ICU). The study will determine the safety and efficacy of a strategy guided by treatment goals based on both intracranial pressure (ICP) and brain tissue oxygen (PbtO2) as compared to a strategy guided by treatment goals based on ICP monitoring alone. Both of these alternative strategies are used in s... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
12/06/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Brain Injuries, Traumatic
Genetic and Functional Analysis of Craniometaphyseal Dysplasia (CMD)
Recruiting
CMD can be inherited in an autosomal dominant or recessive trait. CMD may also be caused by de novo mutations. The goal of this study is to identify genes and regulatory elements on chromosomes that are the cause for CMD. The investigators also study blood samples and tissue samples from patients to learn about the processes that lead to this disorder. The investigators long-term goal is to find mechanisms to slow down bone deposition in CMD patients.
Gender:
ALL
Ages:
All
Trial Updated:
12/06/2024
Locations: University of Connecticut Health Center, Farmington, Connecticut
Conditions: Craniometaphyseal Dysplasia
Genetic and Functional Analysis of Cherubism
Recruiting
The goal of this research study is to identify genes and regulatory elements on chromosomes that cause cherubism. Together with the investigators collaborators the investigators also study blood samples and tissue samples from patients to learn about the processes that lead to this disorder. The long-term goal of researchers involved in this study is to find mechanisms to slow down bone resorption in cherubism patients.
Gender:
ALL
Ages:
All
Trial Updated:
12/06/2024
Locations: University of Connecticut Health Center, Farmington, Connecticut
Conditions: Cherubism
Genetic and Functional Analysis of Aplasia Cutis Congenital (ACC)
Recruiting
The goal of this research study is to identify genes and regulatory elements on chromosomes that cause ACC. The investigators also study tissue samples from patients to learn about the processes that lead to this disorder.
Gender:
ALL
Ages:
All
Trial Updated:
12/06/2024
Locations: University of Connecticut Health Center, Farmington, Connecticut
Conditions: Aplasia Cutis Congenita